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Abstract: Glucocorticoids and mineralocorticoids are key endocrine hormones modulating essential physiological
processes such as energy metabolism, cell growth and differentiation, maintenance of blood pressure and immune
responses. Despite their importance and the fact that their impaired function has been associated with various
diseases, there are only few studies on the potential disruption of glucocorticoid and mineralocorticoid action by
xenobiotics. To facilitate the identification and characterization of such chemicals, we established cell-based as-
says to determine the impact of xenobiotics on different steps of corticosteroid hormone action. Screening of a
small library of chemicals led to the identification of several compounds inhibiting the 11β-hydroxysteroid dehy-
drogenase (11β-HSD) prereceptor enzymes 11β-HSD1 and/or 11β-HSD2 and of chemicals blocking the function
of glucocorticoid receptors (GR) and mineralocorticoid receptors (MR). These findings build a basis to extend the
search for chemicals acting on additional targets of the corticosteroid hormone pathway and to apply in silico
prediction tools in combination with biological testing to screen large numbers of chemicals. The identification
of chemicals interfering with corticosteroid action and the elucidation of the underlying molecular mechanisms
are relevant with respect to the potential contribution to common diseases such as metabolic syndrome, immune
diseases, brain disorders and cancer.
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cell cycle control, and modulation of stress
and inflammatory responses (Fig. 1).
[1]
An
impaired regulation of glucocorticoid ac-
tion has been associated with various com-
plications including metabolic and cardio-
vascular diseases, osteoporosis, cataracts,
immune diseases, mood and cognitive dis-
orders and cancer.
[2−5]
Disturbances of min-
eralocorticoid action have been linked to
the occurrence of hypertension and cardio-
vascular diseases.
[6,7]
The incidence of these
complex diseases increases with increasing
age, and in addition to genetic predispo-
sition, factors including life style and the
exposure to xenobiotics are likely to play
a role in these pathological processes. In de-
veloped countries, the exposure to chemi-
cals from the environment may contribute
to the high incidence of allergic diseases,
cancer and metabolic disturbances.
[8−10]
2. Major Targets of the
Corticosteroid Hormone Pathway
Exogenous chemicals can cause distur-
bances of corticosteroid hormone action
at several steps (Fig. 2). Corticosteroids
are produced in the adrenal cortex involv-
ing several steroidogenic enzymes, and
the synthesis of these hormones is tightly
regulated by corticotrophin releasing fac-
tor (CRF) and adrenocorticotrophic hor-
mone (ACTH) via the hypothalamus-pitu-
itary-adrenal (HPA) axis. Glucocorticoids
control their own synthesis by a negative
feedback response mediated by inhibition
of CRF and ACTH. Upon release into the
blood stream, corticosteroid hormones are
mainly bound to carrier proteins (transcor-
tin, albumin) and reach cells in peripheral
tissues.
At the cellular level, cortisol or corti-
costerone exert their action through GR and
aldosterone acts by activating MR. Impor-
tantly, the local activation of the receptors is
controlled by two distinct 11β-HSD prere-
ceptor enzymes.
[11]
11β-HSD1 is expressed
ubiquitously and catalyzes predominantly
the reduction of inactive 11-ketoglucocor-
ticoids (cortisone, 11-dehydrocortisone)
into active 11β-hydroxyglucocorticoids
(cortisol, corticosterone).
[12]
This enzyme
has a crucial role in potentiating local GR
activation in metabolic processes and in the
immune system.
*Correspondence: Dr. A. Odermatt
Molecular and Systems Toxicology
Department of Pharmaceutical Sciences
University of Basel
Klingelbergstrasse 50
CH-4056 Basel
Tel.: +41 61 267 1530
Fax: +41 61 267 1515
E-mail: alex.odermatt@unibas.ch
1. Physiological Role
of Glucocorticoids and
Mineralocorticoids
Corticosteroid hormones are divided into
glucocorticoids (cortisol in humans and
corticosterone in rodents) and mineralocor-
ticoids (aldosterone). They are involved in
the regulation of many physiological pro-
cesses, including energy metabolism, elec-
trolyte and blood pressure control, bone
metabolism, regulation of brain function,
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The second enzyme, 11β-HSD2, is
expressed in cortical collecting ducts
and distal tubules in the kidney and
in distal colon, where it protects MR
from glucocorticoids by converting
11β-hydroxyglucocorticoids into 11-keto-
glucocorticoids.
[13]
The MR has similar
affinities to bind aldosterone and cortisol
and circulating concentrations of the latter
are 100−1000 times higher, thus, the close
proximity of 11β-HSD2 to the receptor al-
lows aldosterone to bind.
[14]
11β-HSD2 is
also expressed in the syncytiotrophoblast
layer of the human placenta, where it pro-
tects the fetus from high maternal gluco-
corticoid concentrations.
[15]
The tissue-dependent responses upon
activation of GR and MR strongly depend
on the presence of coactivator and corepres-
sor proteins that interact with the receptor
complex, as well as on post-translational
modifications of both receptor and associ-
ated proteins. Finally, enzymes responsible
for the degradation and excretion of the ste-
roid hormones are important to terminate
hormone action.
The proteins described above all recog-
nize corticosteroid molecules despite the
fact that they belong to different classes of
proteins and share very low sequence simi-
larity. This suggests that the binding pockets
of these proteins share structural similarity
and that the chemicals mimicking corticos-
teroid molecules might interact with more
than one of these proteins. Thus, to assess
the potential disruption of corticosteroid
hormone action by exogenous chemicals,
suitable bioassays are required to measure
the activities of the different proteins, with
roles in regulation, biosynthesis, transport,
intracellular metabolism, receptor and deg-
radation.
3. Bioassays
Compared to the extensively studied
field of estrogen- and androgen-like ac-
tions by environmentally relevant chemi-
cals, there are only few studies focusing
on corticosteroid hormones.
[16]
As a start-
ing point to identify chemicals that act on
different steps of glucocorticoid and min-
eralocorticoid regulation, we established
assays to measure the function of human
corticosteroid hormone receptors (GR and
MR) and glucocorticoid metabolizing en-
zymes (11β-HSD1 and 11β-HSD2). To
distinguish between different steps of re-
ceptor activation, the HEK-293 cell line
was selected that is devoid of endogenous
expression of corticosteroid receptors and
hormone metabolizing enzymes.
[17]
Other
cells that are suitable alternatives include
COS-1 and CV-1 cells,
[18]
but they are not
of human origin.
Receptor activity was measured in intact
cells transiently expressing recombinant
receptor or a green-fluorescence (GFP)-
chimeric receptor. This allowed the assess-
ment of the effect of a given chemical on
ligand binding to the receptor, subsequent
translocation of the receptor into the nucle-
us and receptor-mediated transcriptional
activation of a reporter gene. It is important
to distinguish the different steps of recep-
tor activation to understand the inhibitory
mechanism of a chemical. Spironolactone,
as an example, efficiently binds to MR and
induces translocation of the receptor into
the nucleus. It acts as a partial agonist and
therefore antagonizes the potent agonist
effect of aldosterone. The bile acid cheno-
deoxycholic acid inhibits 11β-HSD2 and
leads to glucocorticoid-induced activation
of MR. Although it also induces nuclear
translocation of MR in the absence of
11β-HSD2, chenodeoxycholic acid neither
activates nor antagonizes MR activation by
cortisol or aldosterone.
[19,20]
To assess the effect of chemicals on
11β-HSD prereceptor enzyme function,
the conversion of cortisone to cortisol or the
reverse reaction was measured in lysates or
intact HEK-293 cells stably expressing C-
Fig. 1. Overview of physiological functions that are regulated by corticosteroid hormones
Fig. 2. Schematic overview of targets of corticosteroid hormone action
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terminally FLAG-tagged human 11β-HSD1
or 11β-HSD2.
[21]
The impact of 11β-HSD
enzyme inhibition on receptor function
was determined in cells cotransfected with
11β-HSD1 and GR or 11β-HSD2 and MR,
respectively. As controls for 11β-HSD1 and
11β-HSD2 the well known inhibitor glycyr-
rhetinic acid was used, and for MR and GR,
spironolactone and RU486 were applied to
optimize assay conditions.
The strategy of expressing recombinant
corticosteroid receptors in the presence of
modulatory proteins to identify chemicals
disrupting corticosteroid action by indirect
mechanisms will now be extended. The
impact on receptor function of chemicals
interfering with signaling pathways is cur-
rently under investigation. For the efficient
analysis of chemicals interfering with cor-
ticosteroid hormone action, several cell
models stably expressing different combi-
nations of receptor and modulatory protein
will be constructed.
4. Compounds Inhibiting 11β-HSD2
Liquorice is a well-known endocrine
disruptor inducing corticosteroid hormone
responses.
[22]
Glycyrrhetinic acid, which is
contained in liquorice, has been identified
as a potent inhibitor of 11β-HSD enzymes.
By inhibiting 11β-HSD2, glycyrrhetinic
acid prevents inactivation of cortisol in
cortical collecting ducts and distal tubules
in the kidney, thereby leading to cortisol-
induced MR activation, sodium retention
and hypertension.
[14,23−26]
11β-HSD2 also
has a key function in the regulation of fetal
development
[15]
and protects the fetus from
the high maternal cortisol concentrations.
The intrauterine exposure to elevated levels
of glucocorticoids has been associated with
reduced birth weight and glucose intoler-
ance and cardiovascular complications later
in life,
[27,28]
and evidence has been provided
that this programming is altered through
several generations.
[29]
This indicates a role
for epigenetic factors in the transgenera-
tional information transfer of these altera-
tions. The inhibition of 11β-HSD2 during
pregnancy by glycyrrhetinic acid or its ana-
logue carbenoxolone leads to elevated glu-
cocorticoid levels and causes reduced birth
weight with a higher risk for cardiovascu-
lar disease later in life.
[25]
The inhibition of
11β-HSD2 by chemicals from the environ-
ment in a critical window during pregnancy
is thus expected to cause detrimental effects
and should be considered as a risk factor for
metabolic and cardiovascular diseases.
Grape fruit juice has also been associ-
ated with inhibition of 11β-HSD2,
[30,31]
and naringenin was suggested as the active
compound. However, naringenin is a weak
11β-HSD2 inhibitor (IC
50
> 300 µM),
[21,32]
and it is more likely that other, as yet un-
identified, compounds are responsible for
inhibition of 11β-HSD2. Additional com-
pounds of the triterpenoid and flavonoid
class of chemicals that inhibited 11β-HSD2
include abietic acid, gossypol, magnolol
and tea polyphenols. However, their rela-
tively weak activities observed in intact
cell assays suggest that these compounds
are unlikely to cause physiological conse-
quences by inhibiting 11β-HSD2.
[33]
We then tested about 100 environmen-
tally relevant chemicals that were selected
based on evidence in the literature for po-
tential interference with corticosteroid ac-
tion, for their effect on 11β-HSD2 activity.
In addition to the compounds mentioned
above, abietic acid, fusidic acid, zearale-
none, 4-tert-octylphenol, 4-nonylphenol,
bisphenol A, endosulfan and several di-
thiocarbamates and organotins inhibited
11β-HSD2.
[21]
Among these, abietic acid,
bisphenol A, dithiocarbamates and organo-
tins inhibited 11β-HSD2 at subcytotoxic
concentrations. Dithiocarbamates and or-
ganotins were studied in more detail.
Dithiocarbamate chemicals are widely
used in agriculture as pesticides or fungi-
cides and as vulcanization accelerators in
latex production (mainly in gloves). Dithio-
carbamates are considered to be responsi-
ble for the allergic reactions against rub-
ber products.
[34]
Interestingly, disulfiram,
known asAntabus to treat alcoholic patients,
was also active. Among the dithiocarbam-
ates analyzed, disulfiram and thiram were
most potent with an IC
50
value of 130 nM,
followed by maneb, diethyldithiocarbamate
and zineb.
[35]
The inhibitory potential of
disulfiram and thiram to inhibit 11β-HSD2
was comparable with that for aldehyde de-
hydrogenase. These chemicals irreversibly
inhibited 11β-HSD2, probably by covalent
carbamoylation of catalytically important
cysteine residues. Glutathione protected
11β-HSD2 from inhibition by dithiocar-
bamates, suggesting that these chemicals
are most critical in situations of oxidative
stress, when intracellular glutathione con-
centrations are low. The exposure to the di-
thiocarbamates maneb and zineb has been
associated with acute renal failure and
nephrotic syndrome in agricultural work-
ers, as well as kidney damage and reduced
body weights in the offspring from exposed
pregnant rats. The inhibition of 11β-HSD2
may contribute to some of the observed
toxic effects of these chemicals in kidney
and on blood pressure, as well as in pla-
centa and on fetal development.
We identified several organotins includ-
ing trialkyltins and dialkyltins that potently
inhibited 11β-HSD2 but not 11β-HSD1,
17β-HSD1 or 17β-HSD2.
[36]
They revers-
ibly inhibited the enzyme with comparable
potencies in assays with cell lysates or in-
tact cells. Analysis of the inhibitory mech-
anism suggested that organotins interfere
with 11β-HSD2 function by modification
of cysteine residues. Dithiothreitol, but
not glutathione, protected from organotin-
dependent inhibition. Enhanced glucocor-
ticoid concentrations, due to disruption of
11β-HSD2 function, may contribute to the
observed organotin-dependent toxicity in
some glucocorticoid-sensitive tissues such
as thymus and placenta. Reduced birth
weight and thymus involution, observed
upon exposure to organotins, can also be
caused by excessive glucocorticoid levels.
5. Chemicals Disrupting MR
Activation
The same set of about 100 chemicals
was screened using the MR nuclear trans-
location assay to test them for agonist or an-
tagonist properties. Aldosterone-mediated
nuclear translocation of MR was inhibited
by various chemicals with different prop-
erties, including bisphenol A, endosulfan,
4-nonylphenol, vinclozolin, zearalenone,
and some phthalate derivatives. All of these
chemicals inhibited nuclear translocation
of MR at high concentrations of 20−50 µM
that are unlikely to be physiologically rel-
evant. The screening of this small number
of chemicals showed that chemicals inter-
fering with MR activation exist, although
none of the identified compounds was of
high potency. It cannot be excluded at this
point that some of the identified chemicals
have more pronounced effects under certain
conditions such as oxidative stress or upon
preincubation for a prolonged time. Clearly,
a more extensive screening will be neces-
sary for the identification of chemicals with
physiologically relevant effects.
The contribution of dithiocarbamate-
dependent 11β-HSD2 inhibition to cor-
tisol-induced activation of corticosteroid
receptors is unclear, since we found that
high concentrations of these chemicals also
could block MR and GR. This is in line with
a recent study by Garbrecht et al. who de-
scribed thiram-dependent inhibition of GR
activation.
[37]
An inhibition of 11β-HSD2
and/or MR and GR is only likely to occur
under conditions of glutathione depletion,
and further studies are required to see which
protein is inhibited at the lowest concentra-
tions.
6. Compounds Inhibiting 11β-HSD1
Inhibition of 11β-HSD1-dependent
glucocorticoid activation is currently con-
sidered as a promising strategy to treat pa-
tients with metabolic syndrome
[5]
and many
medium and large pharmaceutical compa-
nies have inhibitor development programs.
While preventing excess production of ac-
tive glucocorticoids is important to avoid
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adverse metabolic effects and inhibition of
11β-HSD1 is beneficial in such situations,
glucocorticoid deficiency has been associ-
ated with impaired immune responses in
inflammatory reactions
[38]
and a reduced
11β-HSD1 expression has been found in
some forms of cancer.
[39,40]
Thus, depend-
ing on the tissue and on the metabolic state,
inhibition of 11β-HSD1 may have different
consequences.
Several compounds inhibiting 11β-
HSD1 were identified upon screening
our small library. Zearalenone, 4-tert-
octylphenol, 4-nonylphenol, methyljas-
monate, dibenzoylmethane and 2,2’-dihy-
droxybiphenyl were weak inhibitors, un-
likely to be of physiological relevance.
[21]
Abietic acid and flavanone as well as some
monohydroxylated flavanone derivatives
were more potent. While abietic acid dis-
played a similar activity as the one observed
with glycyrrhetinic acid and carbenox-
olone and inhibited both 11β-HSD1 and
11β-HSD2, flavanone and its derivatives
selectively inhibited 11β-HSD1 by com-
peting with substrate binding. Analysis of
the structural requirements for the inhibi-
tory effect of flavanones revealed that hy-
droxylation at position 6 leads to reduced
potency. Multiple hydroxylated flavanones
such as the trihydroxylated naringenin
also showed weak inhibitory activities on
11β-HSD enzymes. In addition, the inhibi-
tory effect was lost in flavones, which have
a double bond between atoms C2 and C3.
In a recent study, we provided evidence
that coffee contains compounds inhibiting
11β-HSD1, which might explain in part the
anti-diabetic effect associated with regular
coffee consumption.
[41]
Thus, some natural
compounds may contribute to the positive
health effects of fruits and vegetables by in-
hibiting 11β-HSD1 and they might be used
as food supplements.
11β-HSD1 is a relatively unspecific en-
zyme and accepts several substrates. Sev-
eral reports suggested a role for 11β-HSD1
in phase I detoxification of carbonyl group
containing xenobiotics.
[42,43]
In addition,
several studies recently described an alter-
native role of 11β-HSD1 in the metabolism
of 7-oxygenated cholesterol metabolites.
[44−47]
In intact cells, 11β-HSD1 catalyzed
exclusively the conversion of 7-ketocho-
lesterol to 7β-hydroxycholesterol.
[44−48]
7-Ketocholesterol is a major oxidized cho-
lesterol metabolite and is formed mainly
upon processing cholesterol-rich food. It is
found at micromolar concentrations in cata-
ract lenses and in atherosclerotic plaques.
The role of 11β-HSD1 in these pathological
conditions and the impact of its inhibition
remains to be investigated. Nevertheless,
an accumulation of orally administered
7-ketocholesterol was observed in rats
treated with the inhibitor carbenoxolone.
[44]
More recently, we found that 11β-HSD1
metabolizes 7-ketodehydroepiandrosterone
and 7-ketopregnenolone, suggesting a role
not only in the detoxification of oxidized
cholesterol from food but also of oxidized
steroid hormone metabolites.
[49]
7. Interference of Chemicals with
GR Function
The same set of about 100 chemicals
was screened using our nuclear GR trans-
location assay. Bisphenol A, zearalenone
and some phthalate derivatives inhibited
cortisol-induced nuclear translocation of
GR. These chemicals also inhibited nuclear
MR translocation. BisphenolA and zearale-
none inhibited the function of all four pro-
teins tested, suggesting either an unspecific
mechanism or that these chemicals mimic
the steroid hormone cortisol and are there-
fore recognized by all four proteins. In ad-
dition, dibenzoylmethane and abietic acid
at concentrations of 20−50 µM were shown
to inhibit GR translocation. Due to the high
concentrations required for inhibition, a di-
rect effect on GR was considered not physi-
ologically relevant. In these experiments,
effects on transcriptional expression or on
protein stability after prolonged incubation
with the chemical of interest have not been
assessed.
In a recent study, we found that the or-
ganotin dibutyltin inhibits the activation of
GR at submicromolar concentrations (un-
published observations). An inhibition of
GR function by dibutyltin might explain
some of the immunotoxic effects and ef-
fects on energy metabolism of this chemi-
cal, with relevance to chronic inflammatory
disorders as well as metabolic diseases.
8. Outlook
Screening of a very small library of
environmentally relevant chemicals with
cell-based assays for GR, MR, 11β-HSD1
and 11β-HSD2 led to the identification of
several compounds that interfere with the
function of these proteins, emphasizing the
importance to consider potential interfer-
ences with glucocorticoid and mineralo-
corticoid hormone action for the safety as-
sessment of chemicals. Disruption of cor-
ticosteroid hormone action by xenobiotics
might contribute to metabolic and cardio-
vascular diseases, impaired brain func-
tion, developmental disorders, immune
diseases and cancer. To assess the safety
of chemicals and avoid interferences with
corticosteroid hormone action, the devel-
opment of additional biological in vitro and
in vivo tests is required for the detection of
disturbances at various levels of hormone
action, including HPA axis regulation,
steroidogenesis, transport protein activity,
activities of metabolizing enzymes and re-
ceptor function. The development of suit-
able in silico prediction tools and systemic
approaches, including analyses of effects
of xenobiotics on the transcriptome and
proteome, is necessary for the identifica-
tion of chemicals disrupting corticosteroid
hormone action and to understand their
mechanisms of action.
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